About this trial
Hemato-oncology patients undergoing intensive chemotherapy treatments experience different types of symptoms during and after treatments, which are often refractory to the established therapy. Physical symptoms such as pain, dyspnea, mucositis, insomnia, loss of appetite, constipation and diarrhea, among others, have a huge impact on quality of life, temporarily until symptomatic control, but also permanently with the development of anxiety, depression, long-term fatigue and post-traumatic stress. As recommended by ASCO (American Society of Clinical Oncology), the palliative approach to oncological diseases must be as early as possible and be part of the "standard of care". However, the lack of concrete data on this topic in the last decade served as a barrier to the early integration of this same care for hemato-oncology patients in its various areas. Palliative care presupposes global, interdisciplinary action, carried out by specific teams that must act in situations of incurable or serious illness, in an advanced and progressive phase. The potential benefits can be countless and of significant importance, from the impact on quality of life, symptomatic control, reduction of anxiety and depression and even the promotion of informed and conscious choices at the end of life as well as the reduction of aggressive strategies. used at this stage of the disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Capable of making decisions
Diagnosed with acute myeloid leukemia
Aged 70 years or less
Treated or referred for treatment at the Hematology department of Centro Hospitalar e Universitário de São João.
Disqualifiers
All patients referred for "best supportive care", that is, for supportive care including treatment with cytoreductive intent.
Trial design
Parallel
Treatments tested in this trial
Early palliative care integration
Other interventionEarly follow up by the palliative care team, from diagnosis
Treatment groups
Trial outcomes
Primary outcomes
Fatigue
Assessment of participant fatigue using the Fatigue Scale FACIT. The lower the score, the higher the fatigue.
Quality of life - Functional Scale, Global Health Status, Symptom Scale
Assessment of quality of life using the questionnaire EORTC QLQ-C30. Contains 30 questions assessing three dimensions: 1) Functional Scales: The higher the score, the greater the functional level. 2) Global Health Status: The higher the score, the better the quality of life. 3) Symptom Scales: The higher the score, the greater the severity or frequency of symptoms.
Anxiety and depression
Assessment of anxiety and depression using HADS (Hospital Anxiety and Depression Scale), composed of two subscales for anxiety and depression, each with scores categorized as normal (0-7), mild (8-10), moderate (11-14), and severe (15-21). A score ≥ 11 indicates the presence of anxiety and/or depression.
Symptoms and multidimensional well-being
Assessment of symptoms and multidimensional well-being using the scale IPOS (Palliative care Outcome Scale). Composed by: Q1: Open-ended question, no scoring, used to guide care; Q2-Q5: Scales of 0-4, where higher scores indicate greater symptom severity; Q6-Q8: Positive items, scored 0-4, where lower scores are better; Q10: Open-ended question, no scoring. Sum of the scores from the rated questions (0-68).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Universidade do Porto
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Collaborator
This trial is not recruiting at the moment. You can still explore other options: